MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Thermo Fisher Scientific Long-Term Debt 2011-2026 | TMO
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Thermo Fisher Scientific
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 39.2 B | 31.1 B | 34.7 B | 34.3 B | 34.7 B | - | 17.1 B | 17.7 B | 18.9 B | 15.4 B | 11.5 B | 12.4 B | 9.5 B | 7.03 B | 5.76 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 39.2 B | 5.76 B | 20.6 B |
Quarterly Long-Term Debt Thermo Fisher Scientific
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 35.5 B | 35 B | 34 B | 35.1 B | 35.2 B | 35.4 B | 35.1 B | 33.8 B | 35.1 B | 34.3 B | 28.9 B | - | 33.1 B | 34.7 B | 21.6 B | 18.8 B | 18.6 B | 19.1 B | 21.1 B | 20.6 B | 19.1 B | 17.1 B | 17.1 B | 17.1 B | 17.1 B | 17.7 B | 17.7 B | 17.7 B | 17.7 B | 18.9 B | 18.9 B | 18.9 B | 18.9 B | 15.4 B | 15.4 B | 15.4 B | 15.4 B | 11.4 B | 11.4 B | 11.4 B | 11.4 B | 12.4 B | 12.4 B | 12.4 B | 12.4 B | 9.5 B | 9.5 B | 9.5 B | 9.5 B | 7.03 B | 7.03 B | 7.03 B | 7.03 B | 5.76 B | 5.76 B | 5.76 B | 5.76 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 35.5 B | 5.76 B | 18.7 B |
Long-Term Debt of other stocks in the Diagnostics research industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
15.6 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
2.73 B | $ 116.92 | 2.67 % | $ 35.5 B |  USA |
 |
Aspira Women's Health
AWH
|
1.04 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
1.2 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
3.48 M | $ 1.18 | 0.85 % | $ 6.43 M | USA |
 |
Chembio Diagnostics
CEMI
|
76.7 K | - | 0.22 % | $ 16.8 M | USA |
 |
Enzo Biochem
ENZ
|
189 K | - | -8.98 % | $ 14.8 K | USA |
 |
DermTech
DMTK
|
38 K | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
19.7 M | $ 17.92 | 1.41 % | $ 955 M | USA |
 |
Exact Sciences Corporation
EXAS
|
6.4 M | - | - | $ 19.8 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
32 K | - | - | $ 562 M |  Britain |
|
Akumin
AKU
|
1.25 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Burning Rock Biotech Limited
BNR
|
18.3 M | $ 16.24 | 0.93 % | $ 175 M |  China |
 |
Co-Diagnostics
CODX
|
574 K | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Heska Corporation
HSKA
|
307 K | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
546 K | - | -20.0 % | $ 1.06 M | USA |
 |
Interpace Biosciences
IDXG
|
752 K | $ 1.98 | -0.63 % | $ 8.76 M | USA |
 |
Illumina
ILMN
|
554 M | $ 128.0 | 1.23 % | $ 20.4 B | USA |
 |
Accelerate Diagnostics
AXDX
|
782 K | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
9.74 M | $ 25.19 | 1.45 % | $ 700 M | USA |
 |
Global Cord Blood Corporation
CO
|
147 K | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
54.2 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
388 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
5.49 M | - | 0.12 % | $ 80.1 M | China |
 |
Laboratory Corporation of America Holdings
LH
|
5.08 B | $ 274.72 | 2.06 % | $ 22.9 B | USA |
 |
Charles River Laboratories International
CRL
|
2.14 B | $ 175.07 | 3.26 % | $ 8.68 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.16 B | - | - | $ 10.7 B | USA |
 |
Medpace Holdings
MEDP
|
114 M | $ 520.65 | 2.39 % | $ 15 B | USA |
 |
Danaher Corporation
DHR
|
18.4 B | $ 196.19 | 2.71 % | $ 140 B | USA |
 |
Motus GI Holdings
MOTS
|
1.24 M | - | -34.28 % | $ 263 K |  Israel |
 |
Myriad Genetics
MYGN
|
120 M | $ 4.77 | 0.63 % | $ 442 M | USA |
 |
Neogen Corporation
NEOG
|
875 M | $ 10.34 | 3.61 % | $ 2.24 B | USA |
 |
National Research Corporation
NRC
|
75 M | $ 17.26 | 1.29 % | $ 386 M | USA |
 |
Natera
NTRA
|
282 M | $ 210.83 | 0.75 % | $ 20.7 B | USA |
 |
Invitae Corporation
NVTA
|
3.78 M | - | - | $ 21.2 M | USA |
 |
Organovo Holdings
ONVO
|
421 K | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
1.85 M | - | -16.95 % | $ 1.54 M | USA |
 |
Fulgent Genetics
FLGT
|
360 K | $ 15.83 | -0.5 % | $ 479 M | USA |
 |
Pacific Biosciences of California
PACB
|
56.6 M | $ 1.47 | 2.08 % | $ 441 M | USA |
 |
Guardant Health
GH
|
1.5 B | $ 92.84 | -0.49 % | $ 11.6 B | USA |
 |
PerkinElmer
PKI
|
2.63 B | - | -0.91 % | $ 14.7 B | USA |
 |
QIAGEN N.V.
QGEN
|
1.65 B | - | - | $ 10.6 B |  Niderland |
 |
Psychemedics Corporation
PMD
|
305 K | - | -1.84 % | $ 15.3 M | USA |
 |
Personalis
PSNL
|
34.9 M | $ 6.33 | 2.59 % | $ 375 M | USA |
 |
Anixa Biosciences
ANIX
|
163 K | $ 2.73 | 1.49 % | $ 88.6 K | USA |
 |
Biomerica
BMRA
|
100 K | $ 2.15 | -0.46 % | $ 4.94 M | USA |
 |
Quotient Limited
QTNT
|
145 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
ICON Public Limited Company
ICLR
|
3.4 B | $ 106.54 | -0.58 % | $ 8.79 B |  Irlanda |
 |
Celcuity
CELC
|
138 M | $ 116.94 | 1.19 % | $ 5.47 B | USA |